

February 1, 2011

To whom it may concern:

SEKISUI CHEMICAL CO., LTD.

Establishment of new companies and change in companies' names following the acquisition of U.S.-based Genzyme Corporation's Diagnostics Business

Sekisui Chemical Co., Ltd. (President: Naofumi Negishi, hereinafter "Sekisui Chemical") has established new companies in the U.S. and U.K. , and has altered companies' names in Canada and Germany respectively following its agreement to acquire U.S.-based Genzyme Corporation's Diagnostics business on November 18, 2010, Japan time (November 17, 2010 Boston Time). Now we would like to inform you that these companies start their businesses today.

1. Outline of the announcement made on November 18, 2010

All the assets of the Diagnostics business, including the stocks of the subsidiaries in question will be acquired from Genzyme Corporation.

Since 1995, Genzyme has been an important part of Sekisui Medical's (100% subsidiary of Sekisui Chemical) strategic efforts to expand its sales outside Japan. Specifically, Genzyme & Sekisui Medical have been collaborating since 1995 through a supplier-customer relationship involving the distribution of Sekisui Medical's biochemical diagnostics and the supply of Sekisui Medical's raw materials in the field of infectious disease to the U.S. and Europe.

Thus, the acquisition will enable Sekisui Medical to build upon this historical relationship and establish an even firmer platform for Sekisui Medical's growth outside Japan in the diagnostic field.

< Outline of the business being acquired >

- 1) Business description: Development, manufacture and distribution of clinical diagnostics, mainly for biochemical, diabetes, infectious disease and immunological testing
- 2) Sales: Approx. US\$167 million (for the year ended December 31, 2009)
- 3) Assigned price: US\$265 million

2. Outlines of the newly established subsidiary companies

1) U.S.

- (1) Name of company: Sekisui Diagnostics, LLC
- (2) Location of headquarters: Framingham, Massachusetts
(31 New York Avenue Framingham, MA 01701-9322)
- (3) Representative: Mitsuhisa Manabe (CEO)
- (4) Business description: Development, manufacture and distribution of diagnostics
- (5) Capital: US\$132 million
- (6) Capital structure: 100%-owned subsidiary of Sekisui America Corporation

2) U.K.

- (1) Name of company: Sekisui Diagnostics (UK) Limited
- (2) Location of headquarters: West Malling, Kent
(50 Gibson Drive Kings Hill, West Malling Kent, ME19 4AF)
- (3) Representative: Mitsuhsa Manabe (CEO)
- (4) Business description: Development, manufacture and distribution of diagnostics and raw materials(enzymes)
- (5) Capital: £ 36 million
- (6) Capital structure: 100%-owned subsidiary of Sekisui Europe B.V.

Sekisui America Corporation and Sekisui Europe B.V. are 100%-owned subsidiary companies of Sekisui Chemical.

3. Outlines of the subsidiary companies whose names have been altered

1) Canada

- (1) Name of company: Sekisui Diagnostics P.E.I. Inc.
(Previous name: Genzyme Diagnostics P.E.I. Inc.)
- (2) Location of headquarters: Prince Edward Island
(70 Watts Ave Charlottetown, Prince Edward Island C1E 2B9)
- (3) Representative: Jerome H. Casey (President)
- (4) Business description: Development, manufacture and distribution of diagnostics
- (5) Capital: C\$52 million
- (6) Capital structure: 100%-owned subsidiary of Sekisui Diagnostics, LLC

2) Germany

- (1) Name of company: Sekisui Virotech GmbH (Previous name: Genzyme Virotech GmbH)
- (2) Location of headquarters: Russelsheim, Hessen(Lowenplatz 5, Russelsheim, 65428)
- (3) Representative: Jerome H. Casey (Managing Director Board)
Peter Kessler (Managing Director Board)
- (4) Business description: Development, manufacture and distribution of diagnostics
- (5) Capital: €283,000
- (6) Capital structure: 100%-owned subsidiary of Sekisui Europe B.V.

Press Contact

SEKISUI CHEMICAL CO., LTD.
Corporate Communication Department
Fax: (+81) 3-5521-0510

Disclaimer

This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.